
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 30 years ago
Participantsover 30 years ago
Defining the Patient at Risk for NSAID Toxicityover 30 years ago
GI Toxicity of NSAIDs: Incidence, Complications, Management Strategy





